# A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)

> **NCT01357148** · — · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 143 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Sitagliptin Phosphate/Metformin HCl (JANUMET®)

## Key facts

- **NCT ID:** NCT01357148
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 143 (ACTUAL)
- **Why stopped:** Completion of MK-0431A-235 was rendered unnecessary, as the local oversight authority accepted in its stead the results of another study \[MK-0431-234\].
- **Last updated:** 2015-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01357148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01357148, "A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01357148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*